Richard Proehl becomes vp of manufacturing at CML

Has spent more than 30 years in API manufacturing

Cambridge Major Laboratories (CML), a US producer of pharmaceutical intermediates and APIs, has welcomed Richard Proehl as vice president of manufacturing.

Proehl will be responsible for all plant scale manufacturing operations within the organisation, as well as all engineering and EHS functions. He brings more than 30 years of API manufacturing experience to the firm, based in Germantown, WI and has a strong focus on EHS and Quality Compliance.

‘Rick brings a wealth of experience to our team and his focus on quality and execution is a great fit with our company values,’ said Brian Scanlan, president and ceo of CML.

Prior to joining CML, Proehl was the St Louis site director for Covidien, where he was responsible for the company's largest API plant of about 900 employees.

‘The company's growth has been impressive and I will drive operational discipline in our manufacturing systems as we build on our strong fundamental capabilities and provide our customers with world class API manufacturing operations,’ said Proehl.

You may also like

Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
Ingredients

AAIPharma Charleston sterile manufacturing receives MHRA approval

<p>International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.</p>
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Subscribe now